Xingdong EnjoyMed Camp Hosts Closed-Door Venture Capital Summit with Eight Leading Investment Firms

Winter Is Coming.
Now, the Stark family motto from *A Song of Ice and Fire* should be a phrase silently recited by many in the internet industry.
Winter Is Coming?
The data tell us that the internet healthcare sector is still in its spring.
According to data from VCBeat, the total amount of venture capital investment in China's internet healthcare sector in the first half of 2015 willNearly $800 million, nearly exceeding the total investment and financing amount for the entire year of 2014.
This time, the “Star Health Investment Camp” specially invited star investment institutionsAurora Venture Capital, Fosun Pharma, Sequoia Capital, Legend Capital, BlueRun Ventures, Lenovo Star, SAIF Partners, Vivo Capital, Star InvestorDeng Feng, Xu Qian, Chen Penghui, Cai Daqing, Chen Weiguang, Lu Gang, Yang Dong, Cao YiboParticipate in the closed-door VC session to engage in face-to-face discussions with participants of the current Xiangyihui VC Camp, exchanging views on entrepreneurship and capital trends.

(Note: Investment institutions and investors are listed in alphabetical order by Pinyin; no ranking is implied.)

Aurora Venture Capital



————————————————————————————————

Northern Light Venture Capital, founded in 2005, currently manages assets totaling nearly RMB 10 billion and has invested in over 100 companies across sectors including high-tech, new media, telecommunications (TMT), clean technology, consumer goods, and healthcare.
Investment stages primarily focus on the early stage and the initial growth stage, i.e., the 4–5 years prior to a company’s initial public offering (IPO), while also strategically participating in investment opportunities during the 1–2 years preceding the IPO.
Selected Investment Projects:Yixinli / Renxin Network Technology, Xinlianda Technology, Boyibang / Shanghai Geping.

◆Deng Feng


One of the founders of Northern Light Venture Capital, with over 20 years of technical and management experience in the venture capital, computer, telecommunications, and data networking industries.

“Aurora aims to be a farmer rather than a hunter; this is our investment philosophy. Our team is a blend of local talent and returnees, with the majority having engineering backgrounds. A significant number also possess experience in corporate operations or entrepreneurship—these are our distinguishing features. When these elements converge, you will find that we are better suited for investing in technology companies and for making early-stage investments. This is precisely the endeavor we are passionate about.”

Fosun Pharma



————————————————————————————————

Fosun Pharma is a pharmaceutical company focused on the modern biopharmaceutical and healthcare industry. Founded in 1994, it was listed on the Shanghai Stock Exchange in August 1998 and on the Main Board of The Stock Exchange of Hong Kong in October 2012.
Selected Investment Projects:WeDoctor Group (formerly Guahao.com)。

◆ Xu Qian


Deputy General Manager of the Investment Headquarters at Fosun Pharma, with over 13 years of experience in the investment industry. Has invested in multiple companies, including Guahao.com, Buchang Pharmaceuticals, and Mingyang Smart Energy (NYSE: MY).

“The business environment in China is relatively complex and places significant emphasis on interpersonal relationships. To enhance the success rate and return on investment of projects, angel investors typically engage in the management of their portfolio companies. However, the extent and manner of such involvement vary, influenced by factors such as the professional backgrounds and personal styles of both the angel investors and the founders.”

Sequoia Capital



————————————————————————————————

Sequoia Capital was founded in Silicon Valley, USA, in 1972. It has established localized funds in four countries with the greatest innovation or development potential globally: the United States, China, India, and Israel. Currently, it manages over 30 equity investment funds, with a total fund size exceeding $13 billion. The total market capitalization of companies invested in by Sequoia Capital that have gone public accounts for more than 20% of the total market capitalization of the Nasdaq.
Sequoia Capital China currently manages eight U.S. dollar-denominated funds and three RMB-denominated funds, with total assets under management exceeding RMB 30 billion, targeting companies with distinct technological advantages and innovative business models that demonstrate high growth potential and strong return prospects.
Sequoia’s four key focus areas are Technology/Media, Consumer Products/Services, Healthcare, and New Energy/Clean Tech/Advanced Manufacturing.
Selected Investment Projects:WeDoctor Group (formerly Guahao.com), Xingren Doctor, Dayima, Kangda Pre-diagnosis, Gengmei APP, Medlinker。

◆ Chen Penghui


Partner at Sequoia Capital China. Focus area: healthcare and medical industry. Joined Sequoia in 2014. Previously served as Head and Managing Director of the Healthcare Fund at China Everbright Limited, with investments including BGI Genomics, Amcare, Zhejiang Beta Pharma, and Kunming Jida Pharmaceutical.

“Only by delivering products and services that provide patients with a better experience, foster greater willingness among physicians to adopt them, and establish a superior business model can a company become a great player in the mobile health industry.”

Legend Capital



————————————————————————————————

Legend Capital, established in 2001, adheres to the investment philosophy of “business first, people foremost.” With over RMB 20 billion in assets under management, it is committed to becoming a respected investor. Healthcare is a key investment sector for Legend Capital, with cumulative investments exceeding RMB 2 billion.
Selected Investment Projects:Tongxin Medical Alliance, Gairui Health, Oncology News。

◆Cai Daqing


Currently serves as Managing Director at Legend Capital. Joined Legend Capital in 2011 and participated in establishing the healthcare team and the specialized medical fund. Serves on the boards of directors of several companies, including Berry Genomics and InnoCare Pharma.

“Grow together with innovators in technology, business models, and industry landscapes.”

BlueRun Ventures



————————————————————————————————

BlueRun Ventures is an early-stage venture capital fund focused on mobile internet and enterprise applications. Established in 1998, BlueRun Ventures manages over $1 billion in total capital. As a global venture capital firm, it has offices in Beijing, Shanghai, Silicon Valley (USA), and Seoul.
Selected Investment Projects:Spring Rain Doctor, Apricot Forest, Ledongli, Ran Technology, Squirrel Interconnect, GeneCat, Asthma Manager。

◆Chen Weiguang


Joined BlueRun Ventures in 2001 as a Partner, based in Beijing, with a focus on early-stage investments in mobile healthcare, mobile internet, big data, and enterprise applications. Currently serves as a board member for several innovative companies, including Ganji.com, Chunyu Doctor, Medtrees, Echo, and QingCloud.

“Entrepreneurship means stepping off the path laid out by conventional wisdom to discover your own strategic opportunity. This opportunity is not found where crowds gather, nor is it defined by what investors say. It lies right beneath our feet. With unwavering belief, we will forge ahead, exploring and finding our way step by step.”

Legend Star



————————————————————————————————

Since 2008, the “entrepreneurship training + open platform + angel investment” trinity model pioneered by Legend Star has gained high recognition and enthusiastic support from entrepreneurs. To date, the Legend Star CEO Executive Training Program has received over 8,000 business plans and enrollment applications. It has trained more than 150 outstanding entrepreneurs in the healthcare industry, covering fields such as mobile health, new drug development, and medical devices, and has promoted incubation efforts focused on “cross-boundary innovation and collaborative entrepreneurship” across these three sectors.
Legend Star’s investment stages cover angel rounds and Pre-A rounds. It has completed investments in over 100 projects, fostering a cohort of high-growth companies such as LeDou Games, FACE++, Burning Rock Biotech, PegBio, and Tianjin MicroNano Core.
Selected Investment Projects:Tianjin Micro-Nano Core, Tongxin Medical Union。

◆Lu Gang


Executive Director and Executive Deputy General Manager of Legend Star. Joined Legend Holdings in 2004, representing investors to evaluate, invest in, and manage venture capital firms, with in-depth research in venture capital investment.

“Embarking on a mobile health startup requires not only abundant passion but also exceptional entrepreneurial wisdom and long-term patience. After all, this sector differs from the transformation of most traditional businesses; it is an industry under strict government regulation with highly complex stakeholder interests. It places exceptionally high demands on entrepreneurs’ wisdom in understanding the ecosystem and exploring business models, as well as their execution capabilities, patience, and personal mindset.”

SoftBank SAIF Partners



————————————————————————————————

SoftBank SAIF Partners was established in 2001 and was renamed SAIF Partners Asia in 2009. It currently manages approximately $4 billion in assets, including four US dollar-denominated funds and several RMB-denominated funds under its umbrella, making it one of the largest venture capital and growth-equity investment firms in Asia.
Selected Investment Projects:Shikang Yisheng, Tanghu Technology, Huiying Medical。

◆Yang Dong


Partner at SoftBank SAIF Partners, a founding member of the fund’s team; recognized as one of China’s Top 10 Venture Capital Entrepreneurs in 2007 and listed among Forbes’ Best Chinese Venture Investors in 2008.

“Angel investors look at the team and vision, Series A looks at the product, Series B looks at data, Series C looks at revenue, and IPOs look at profits.”

OrbiMed Capital



————————————————————————————————

Vivo Capital, founded in 1996, is dedicated to investing in and building high-quality enterprises in the life sciences and healthcare sectors across China and the United States. Managing over $1.8 billion in assets, Vivo employs a unique, multi-faceted investment strategy to identify and invest in high-potential companies.
In the United States, OrbiMed’s innovative medical products are all in late-stage development or early commercialization. In Greater China, it tends to invest in life science and healthcare companies that have entered the growth stage. OrbiMed has offices in Palo Alto, California, USA, and in Shanghai, Beijing, and Chengdu, China.
Selected Investment Projects:Gengmei APP。

◆ Cao Yibo


Currently Managing Director at Vivo Capital, with extensive experience in China’s pharmaceutical industry. Prior to joining Vivo Capital, served as Head of Strategy and Business Development for Nycomed’s North Asia region, where he helped restructure Nycomed’s operations in China.

“As long as the products of mobile healthcare companies meet the required standards, professional investment institutions are not only willing to invest but also eager to help design their development strategies and even endorse them to attract resources and collaborators.”

Registration Open for StarMed Venture Camp
Late October to mid-November (on weekends): A total of five 7-day courses
Beijing

Related Matters
1. Registration Deadline:
October 16, 2015

2. Eligible Applicants:
Early Entrepreneur in Internet Healthcare

3. Event Overview:
“Xingdong Xiangyi Hui” Venture Capital Camp is a training program designed for entrepreneurs in the internet healthcare sector. Its primary objective is to address the three major challenges faced by these entrepreneurs—securing funding, recruiting talent, and defining strategic direction—by navigating common early-stage startup pitfalls. The curriculum incorporates practical sandbox simulations, themed lectures by guest speakers, closed-door meetings with investors, roundtable discussions with industry leaders, and interactive group sessions among participants.

Note: Only 24 enrollment slots are available for this session.

Scan the QR code to register or clickOriginal Article Link！！！